A comparative analysis of effectiveness, tolerance and cost of second generation antidepressants in France.

##plugins.themes.academic_pro.article.sidebar##

Published Jul 20, 2015
Download
pdf
Vol. 93 No. 3 (2015): Issue Mar 2015

##plugins.themes.academic_pro.article.main##

Guillaume Fond

Abstract

While French authorities point to the need for rational prescribing, especially concerning psychotropic drugs, few data on the prescription of second-generation antidepressants (SGA) are synthesized for clinicians' use. Our objective is to carry out a comparative analysis of effectiveness and tolerability / acceptability of SGA. Considering the benefit/risk ratio and the cost (generic), the first-line treatment for a major depressive episode may be currently sertraline (50 mg / d). It may however have more digestive side effects than other SSRIs (due to the serotonin action), which calls for caution while increasing doses. Fluoxetine seems relevant in treatment of negative symptoms of schizophrenia (20mg / d) and in bulimia (60mg / d). Fluvoxamine seems relevant in the case of sexual side effects with a previous SSRI, in treatment of anxiety disorders (it's affinity for sigma receptors may confer a specific action) and in psychotic depression. Mirtazapine may be a treatment of interest when a fast remission of depressive symptoms (especially insomnia) is warranted but its tolerance profile makes it difficult to use.

Keywords:

Second generation antidepressive agents, effectiveness, acceptability, cost, serotonin reuptake inhibitors

##plugins.themes.academic_pro.article.details##

References

  1. http://www.ccomptes.fr/fr/CC/documents/RELFSS/Rapport_securite_sociale_ 2011_maitrise_depenses_medicaments_4.pdf.
  2. http://www.has-sante.fr/portail/jcms/c_240709 /prise-en-charge-dun-episodedepressif- en-ambulatoire?xtmc=antid%C3%A9presseurs& xtcr=19
  3. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size an d burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(9): 655-79
  4. DSM-IV-TR.
  5. http://www.giesips.org/pages/simple_identifie.aspx.
  6. Cipriani A, Koesters M, Furukawa TA, Nose M, Purgato M, Omori IM, et al. Dulo xetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012; 10: CD006533
  7. http://www.has-sante.fr/portail/upload/d ocs/application/pdf/2009- 10/synthese_davis _cymbalta_-_ct-6356.pdf
  8. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (2): CD006532
  9. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2005; (4): CD004185
  10. Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2010; (3): CD006114
  11. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; (3): CD006529
  12. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011; 12: CD006528
  13. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H,et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and metaanalysis. J Clin Psychiatry. 2008; 69(9): 1404-15
  14. Katzman MA, Tricco AC, McIntosh D, Filteau MJ, Bleau P, Chokka PR, et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry. 2007; 68(12): 1845-59
  15. Bernard K, Penelaud PF, Mocaer E, Donazzolo Y. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers. J Clin Psychopharmacol. 2011; 31(4): 441-8
  16. de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol. 2012; 27(1): 8-16
  17. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746-58
  18. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013; 28(1): 33-45
  19. Canton J, Scott KM, Glue P. Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2012; 8: 203-15
  20. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001; 21(3): 311-24
  21. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000; 15 Suppl 2: S15-23
  22. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012; 15(6): 825- 40
  23. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr. 2009; 14(1 Suppl 1): 25-31
  24. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006; (1): CD002795
  25. Stein DJ, Seedat S, van der Linden GJ, Zungu-Dirwayi N. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2000; 15 Suppl 2: S31-9
  26. Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011; 72(8): 1144-51
  27. Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011; 31(5): 582-6
  28. Thaler K, Delivuk M, Chapman A, Gaynes BN, Kaminski A, Gartlehner G. Second-generation antidepressants for seasonal affective disorder. Cochrane Database Syst Rev. 2011; 12: CD008591